David Siderovski

Siderovski attended Earl Haig Secondary School in North York, Ontario, graduating in 1985. In 1989, Siderovski graduated with a BSc from Queen's University in Kingston, Ontario.[3]

David Siderovski, outside Summerhill House (Queen's University, Kingston, ON), holding the 1989 HRH Prince of Wales Prize

Siderovski began his PhD training at the University of Toronto in May 1989. During his fifth year of his PhD, he began full-time work as a research scientist in the Quantitative Biology Laboratory of the Amgen Research Institute, Toronto.[4] He successfully defended his PhD thesis in November 1997.[5] He left the Amgen Research Institute in December 1998, having contributed to three patents as a co-inventor.[6][7][8]

After completing his industrial postdoctoral position at the Amgen Research Institute in 1998,[4] Siderovski joined the faculty at the University of North Carolina at Chapel Hill as a tenure-track assistant professor of pharmacology. His earliest publications, starting with a brief original report in Current Biology,[9] chronicle his independent discovery[10] of the RGS protein superfamily,[11][12][13] and determinations of their varied protein structures[14][15] and cellular functions.[16] One of these early reports[14] was co-authored by two Nobel laureates: Alfred G. Gilman and Robert Lefkowitz. [17]

In 2004, Siderovski was named the top American Pharmacologist under 40 and awarded the John J. Abel Award by the American Society for Pharmacology and Experimental Therapeutics.[18]

From 2006 to 2012, Siderovski was the Thomas J. Dark Basic Science Director of UNC's Medical Scientist Training Program and directly responsible for assisting MD/PhD combined-degree trainees through their progress to PhD completion.[19] In August 2014, Siderovski was appointed Director of the West Virginia University School of Medicine MD/PhD Scholars Program.[20] Siderovski has been serving as Editorial Board Member for the Journal of Biological Chemistry since 2012.[21]